Study of Subcutaneous Immunoglobulin in Patients With PID Requiring IgG Replacement Therapy
Public ClinicalTrials.gov record NCT00419341. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase III Open-Label, Prospective, Multicenter Study of the Efficacy, Tolerability, Safety, and Pharmacokinetics of Immune Globulin Subcutaneous (Human), IgPro20 in Subjects With Primary Immunodeficiency (PID)
Study identification
- NCT ID
- NCT00419341
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- CSL Behring
- Industry
- Enrollment
- 49 participants
Conditions and interventions
Conditions
Interventions
- Human Normal Immunoglobulin for Subcutaneous Administration Biological
Biological
Eligibility (public fields only)
- Age range
- 2 Years to 75 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 31, 2006
- Primary completion
- Sep 30, 2008
- Completion
- Sep 30, 2008
- Last update posted
- Jan 24, 2013
2006 – 2008
United States locations
- U.S. sites
- 13
- U.S. states
- 11
- U.S. cities
- 12
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Study Site | Los Angeles | California | 90025 | — |
| Study Site | Los Angeles | California | 90027 | — |
| Study Site | Centennial | Colorado | 80112 | — |
| Study Site | North Palm Beach | Florida | 33408 | — |
| Study Site | Atlanta | Georgia | 30322 | — |
| Study Site | Fort Wayne | Indiana | 46815 | — |
| Study Site | Indianapolis | Indiana | 46202 | — |
| Study Site | Iowa City | Iowa | 52242 | — |
| Study Site | St Louis | Missouri | 63104-1095 | — |
| Study Site | Newark | New Jersey | 07103 | — |
| Study Site | New York | New York | 10029 | — |
| Study Site | Philadelphia | Pennsylvania | 19104 | — |
| Study Site | Dallas | Texas | 75230 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00419341, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 24, 2013 · Synced Jul 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00419341 live on ClinicalTrials.gov.